Introduction: Recent data from the American Society of Clinical Oncology (ASCO) GI Cancers Symposium 2025,…

In the rapidly evolving field of cancer treatment, the application of comprehensive genomic profiling (CGP)…

The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study,…

EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3…

The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.